Publication
Baseline susceptibility of primary HIV-2 to entry inhibitors
| dc.contributor.author | Borrego, Pedro | |
| dc.contributor.author | Calado, Rita | |
| dc.contributor.author | Marcelino, José M | |
| dc.contributor.author | Bártolo, Inês | |
| dc.contributor.author | Rocha, Cheila | |
| dc.contributor.author | Cavaco-Silva, Patrícia | |
| dc.contributor.author | Doroana, Manuela | |
| dc.contributor.author | Antunes, Francisco | |
| dc.contributor.author | Maltez, Fernando | |
| dc.contributor.author | Caixas, Umbelina | |
| dc.contributor.author | Barroso, Helena | |
| dc.contributor.author | Taveira, Nuno | |
| dc.date.accessioned | 2013-11-29T12:35:32Z | |
| dc.date.available | 2013-11-29T12:35:32Z | |
| dc.date.issued | 2012-01 | |
| dc.description | This is the author’s version of a work accepted for publication by International Medical Press. Changes resulting from the publishing process, including peer review, editing and formatting, might not be reflected in this document. A definitive version was published in Antiviral Therapy, 17 (3): 565-570, January © 2012 International Medical Press. | |
| dc.description.abstract | Background: The baseline susceptibility of primary HIV-2 to maraviroc (MVC) and other entry inhibitors is currently unknown. | por |
| dc.description.abstract | Methods: The susceptibility of 19 HIV-2 isolates obtained from asymptomatic and AIDS patients and seven HIV-1 clinical isolates to the fusion inhibitors enfuvirtide (ENF) and T-1249, and to the coreceptor antagonists AMD3100, TAK-779 and MVC, was measured using a TZM-bl cellbased assay. The 50% inhibitory concentration (IC50), 90% inhibitory concentration (IC90) and dose–response curve slopes were determined for each drug. | por |
| dc.description.abstract | on HIV-2 than on HIV-1 (211- and 2-fold, respectively). AMD3100 and TAK-779 inhibited HIV-2 and HIV-1 CXCR4 tropic (X4) and CCR5 tropic (R5) variants with similar IC50 and IC90 values. MVC, however, inhibited the replication of R5 HIV-2 variants with significantly higher IC90 values (42.7 versus 9.7 nM; P<0.0001) and lower slope values (0.7 versus 1.3; P<0.0001) than HIV-1. HIV-2 R5 variants derived from AIDS patients were significantly less sensitive to MVC than variants from asymptomatic patients, this being inversely correlated with the absolute number of CD4+ T-cells. | por |
| dc.description.abstract | Conclusions: T-1249 is a potent inhibitor of HIV-2 replication indicating that new fusion inhibitors might be useful to treat HIV-2 infection. Coreceptor antagonists TAK- 779 and AMD3100 are also potent inhibitors of HIV-2 replication. The reduced sensitivity of R5 variants to MVC, especially in severely immunodeficient patients, indicates that the treatment of HIV-2-infected patients with MVC might require higher dosages than those used in HIV-1 patients, and should be adjusted to the disease stage. | por |
| dc.identifier.citation | Antiviral Therapy 2012; 17:565-570 doi: 10.3851/IMP1996 | por |
| dc.identifier.issn | 2040-2058 | |
| dc.identifier.issn | 1359-6535 | |
| dc.identifier.uri | http://hdl.handle.net/10400.26/4993 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | International Medical Press | por |
| dc.relation.publisherversion | http://www.intmedpress.com/journals/avt/abstract.cfm?id=1996&pid=88 | por |
| dc.subject | HIV-2 | por |
| dc.subject | inhibitors | por |
| dc.title | Baseline susceptibility of primary HIV-2 to entry inhibitors | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 570 | por |
| oaire.citation.startPage | 565 | por |
| oaire.citation.title | Antiviral Therapy | por |
| oaire.citation.volume | 17, n.º 3 | por |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |